Literature DB >> 30413323

Natural history of papillary thyroid microcarcinoma: Kinetic analyses on tumor volume during active surveillance and before presentation.

Akira Miyauchi1, Takumi Kudo2, Yasuhiro Ito3, Hitomi Oda3, Masatoshi Yamamoto3, Hisanori Sasai4, Takuya Higashiyama3, Hiroo Masuoka3, Mitsuhiro Fukushima3, Minoru Kihara3, Akihiro Miya3.   

Abstract

BACKGROUND: We report on the growth of papillary microcarcinoma during active surveillance and before clinical presentation.
METHODS: We conducted a retrospective study of 169 patients with papillary microcarcinoma who were enrolled in active surveillance at our hospital between 2000 and 2004. Patients were followed for a median of 10.1 years using serial ultrasonography (median, 12 examinations), used to calculate the tumor doubling time. To contextualize tumor growth rates during active surveillance, we calculated the hypothetical tumor doubling time before clinical presentation. To resolve the limitations in tumor doubling time, tumor doubling rates were inversely transformed into doubling rates.
RESULTS: The doubling rates (per year) during active surveillance (median: 0.0) were >0.5, 0.1 to 0.5, -0.1 to 0.1, and <-0.1 in 5, 38, 97, and 29 cases, respectively. The proportions of tumors with rather rapid growth, slow growth, stable, and a decrease in size were 3%, 22%, 57%, and 17%, respectively.
CONCLUSION: Tumor growth of papillary microcarcinomas varies from rather rapid growth to a decrease in size during active surveillance.
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2018        PMID: 30413323     DOI: 10.1016/j.surg.2018.07.045

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  21 in total

Review 1.  Molecular Pathology of Non-familial Follicular Epithelial-Derived Thyroid Cancer in Adults: From RAS/BRAF-like Tumor Designations to Molecular Risk Stratification.

Authors:  Paula Soares; Antónia Afonso Póvoa; Miguel Melo; João Vinagre; Valdemar Máximo; Catarina Eloy; José Manuel Cameselle-Teijeiro; Manuel Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2021-03-02       Impact factor: 3.943

2.  Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.

Authors:  Tiffany Yeh; Michele Yeung; Eric J Sherman; R Michael Tuttle; Mona M Sabra
Journal:  Thyroid       Date:  2020-04-20       Impact factor: 6.568

3.  Successful dose escalation of lenvatinib for thyroid cancer after disease progression.

Authors:  Chie Masaki; Kiminori Sugino; Junko Akaishi; Kiyomi Y Hames; Chisato Tomoda; Akifumi Suzuki; Kenichi Matsuzu; Keiko Ohkuwa; Wataru Kitagawa; Mitsuji Nagahama; Koichi Ito
Journal:  Endocrine       Date:  2022-06-23       Impact factor: 3.925

4.  Thyroid-Stimulating Hormone, Age, and Tumor Size are Risk Factors for Progression During Active Surveillance of Low-Risk Papillary Thyroid Microcarcinoma in Adults.

Authors:  Yasuhiro Ito; Akira Miyauchi; Makoto Fujishima; Takuya Noda; Tsutomu Sano; Takahiro Sasaki; Taketoshi Kishi; Tomohiko Nakamura
Journal:  World J Surg       Date:  2022-10-02       Impact factor: 3.282

5.  Kinetic analysis of the growth rate of sporadic and hereditary medullary thyroid carcinoma: comparing the postoperative calcitonin-doubling rate with the hypothetical preoperative tumor volume-doubling rate.

Authors:  Minoru Kihara; Akira Miyauchi; Hiroo Masuoka; Takuya Higashiyama; Yasuhiro Ito; Akihiro Miya
Journal:  Thyroid Res       Date:  2020-07-21

6.  Association of Patient Age With Progression of Low-risk Papillary Thyroid Carcinoma Under Active Surveillance: A Systematic Review and Meta-analysis.

Authors:  Alexandra Koshkina; Rouhi Fazelzad; Iwao Sugitani; Akira Miyauchi; Lehana Thabane; David P Goldstein; Sangeet Ghai; Anna M Sawka
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-06-01       Impact factor: 6.223

7.  Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma.

Authors:  Yasuhiro Ito; Naoyoshi Onoda; Takumi Kudo; Hiroo Masuoka; Takuya Higashiyama; Minoru Kihara; Akihiro Miya; Akira Miyauchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

8.  Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Differentiated Thyroid Carcinoma Having Distant Metastasis: A Comparison With Thyroglobulin-doubling Rate and Tumor Volume-doubling Rate.

Authors:  Yasuhiro Ito; Naoyoshi Onoda; Minoru Kihara; Akihiro Miya; Akira Miyauchi
Journal:  In Vivo       Date:  2021 Mar-Apr       Impact factor: 2.155

Review 9.  Active Surveillance of Thyroid Microcarcinomas: a Critical View.

Authors:  Claudio R Cernea; Leandro Luongo Matos; Cecília Eugênio; Giovanna Mattos Ferreira; Yasmin Sa Cerqueira; Ana Kober N Leite; Felipe A B Vanderlei; Dorival de Carlucci; Renato N Gotoda; Flávio C Hojaij; Vergilius J F Araújo-Filho
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

10.  Understanding surgical decision-making in older adults with differentiated thyroid cancer: A discrete choice experiment.

Authors:  Whitney Sutton; Becky Genberg; Jason D Prescott; Dorry L Segev; Martha A Zeiger; Karen Bandeen-Roche; Aarti Mathur
Journal:  Surgery       Date:  2020-05-28       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.